文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

儿童遗传性骨髓衰竭综合征的单倍体相合造血干细胞移植:代表EBMT重型再生障碍性贫血与儿童疾病工作组的回顾性分析

HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties.
PubMed 文献 · Am J Hematol · 2024-03-18

这项代表EBMT SAAWP和PDWP的回顾性研究纳入162例接受单倍体相合移植的遗传性骨髓衰竭综合征患儿(中位年龄7.4岁),比较不同体内外T细胞去除方案。2年总生存率67%、无GvHD/排斥生存率53%;TCRαβ+/CD19+去除组急性及慢性GvHD发生率更低,总生存率79%(p=0.013)、GRFS 71%(p<0.001)。

要点

  • 162例患儿中范可尼贫血最常见(70.1%),中位随访43.4个月。
  • 2年总生存率67%,无GvHD/排斥生存率53%。
  • TCRαβ+/CD19+去除组总生存率79%(p=0.013)、GRFS 71%(p<0.001),急慢性GvHD更低。

核心结论

  • 这项大型回顾性研究支持单倍体相合移植在遗传性骨髓衰竭综合征患者中的安全性和可行性。
  • 与其他平台相比,TCRαβ+/CD19+去除可提供更高的生存机会,并显著降低严重急性和慢性GvHD风险。

研究设计与样本

  • 代表EBMT重型再生障碍性贫血工作组(SAAWP)和儿童疾病工作组(PDWP)开展的回顾性研究。
  • 纳入162例接受单倍体相合造血干细胞移植的遗传性骨髓衰竭综合征患者,中位年龄7.4岁。
  • 按T细胞去除方式分为四类:TCRαβ+/CD19+去除(43.8%)、移植后环磷酰胺(PTCy)T细胞充足(34.0%)、ATG/阿仑单抗体内T细胞去除(14.8%)、CD34+阳性选择(7.4%)。

主要发现

  • 中性粒细胞和血小板植入的累积发生率分别为84%和76%,原发性和继发性植入失败分别为10%和8%。
  • 急性GvHD III-IV级100天累积发生率为13%,广泛性慢性GvHD 24个月累积发生率为4%。
  • 中位随访43.4个月后,2年总生存率和无GvHD/排斥生存率分别为67%和53%。
  • TCR CD3+αβ+/CD19+去除组急性和慢性GvHD发生率均显著更低,总生存率79%(p=0.013)、GRFS 71%(p<0.001)更高。
  • 不同诊断和预处理方案之间未观察到结局的显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims to report the current outcomes of haplo-SCT in I-BMFs, comparing the different in vivo and ex vivo T-cell depletion approaches. One hundred and sixty-two I-BMF patients who underwent haplo-SCT (median age 7.4 years) have been registered. Fanconi Anemia was the most represented diagnosis (70.1%). Based on different T-cell depletion (TCD) approaches, four categories were identified: (1) TCRαβ+/CD19+-depletion (43.8%); (2) T-repleted with post-transplant Cyclophosphamide (PTCy, 34.0%); (3) In-vivo T-depletion with ATG/alemtuzumab (14.8%); (4) CD34+ positive selection (7.4%). The cumulative incidences (CI) of neutrophil and platelet engraftment were 84% and 76% respectively, while that of primary and secondary graft failure was 10% and 8% respectively. The 100-day CI of acute GvHD grade III-IV(95% CI) was 13%, while the 24-month CI of extensive chronic GvHD was 4%. After a median follow-up of 43.4 months, the 2-year overall survival(OS) and GvHD/Rejection-free Survival (GRFS) probabilities are 67% and 53%, respectively. The TCR CD3+αβ+/CD19+ depletion group showed a significantly lower incidence of both acute and chronic GvHD and higher OS (79%; p0.013) and GRFS (71%; p < .001), while no significant differences in outcomes have been observed by different diagnosis and conditioning regimens. This large retrospective study supports the safety and feasibility of haplo-SCT in I-BMF patients. TCRαβ+/CD19+ depletion offers higher chances of patients' survival, with a significantly lower risk of severe a- and c-GvHD in I-BMFs compared to other platforms.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Giardino S, Eikema DJ, Piepenbroek B, et al. HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties. Am J Hematol. 2024. PMID: 38497679. doi:10.1002/ajh.27293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。